Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,494.00
(
0.67%
)
US TECH 100
28,763.17
(
0.61%
)
Dow Jones
50,027.19
(
0.67%
)
Brent Oil
103.55
(
-0.14%
)
Bitcoin
81,961.01
(
3.38%
)
News Focus
News Focus
Post# of 257563
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122981
Boards Moderated 9
Alias Born 09/05/2002

DewDiligence

Member Level

Re: ariadndndough post# 152842

Wednesday, 11/21/2012 3:12:25 PM

Wednesday, November 21, 2012 3:12:25 PM

Post# of 257563
The write-up you posted on AMRN and Pronova appears to be comparing apples and oranges. Pronova’s revenues are in the form of royalties from GSK and other licensees, but the author uses the worldwide in-market sales of Lovaza (under various aliases) as a datapoint in the valuation analysis.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Where Real Traders Talk Markets

Join thousands of traders sharing insights, catalysts, and charts.

Join Today